Tim KantersHealth Technology Assessment Of Orphan Drugs:The example of Pompe disease8 december 2016
Linda MuijsersDe kracht van duaal bestuur7 oktober 2016
Maarten JanssenSituated Novelty:a study on healthcare innovation and its governance16 september 2016
Leander BuismanEarly Cost-Effectiveness of Medical Tests in Rheumatoid Arthritis and Ischemic Stroke30 juni 2016
Femke VennikInteracting Patients:The construction of active patientship in quality improvement initiatives24 juni 2016
David RappangeFuture Health:a policy and an individual perspective19 mei 2016
Liesbeth Lawerman - de WeteringValuing and Refining Outcome Measures for Economic Evaluations in Health Care12 mei 2016
Wameq RazaEvaluations of Social Safety-nets in Bangladesh and India28 april 2016
Suzanne H.C.M. van VeenEvaluating and Improving the Predictive Performance of Risk Equalization Models in Health Insurance Markets7 april 2016
Hedwig Maria Sluimer-BlommesteinThe Added Value of Real-World Evidence1 april 2016
Shamiso ZinzombeThe right to health, pharmaceutical corporations and intellectual property: access to medicine3 maart 2016
Sarah SlaghuisRiding The Waves Of Quality ImprovementSustainability and spread in a Dutch quality improvement program for long-term care 22 januari 2016
Angelica Sousa FragosoThe relation between the health workforce distribution and maternal and child health inequalities6 januari 2016